Long-Term follow-up of a Phase I/II Randomized, Placebo-Controlled Trial of Palifermin to Prevent Graft-versus-Host Disease (GVHD) after Related Donor Allogeneic Hematopoietic Cell Transplantation (HCT)  by Levine, John E. et al.
Biology of Blood and Marrow Transplantation 14:1017-1021 (2008)
Q 2008 American Society for Blood and Marrow Transplantation
1083-8791/08/1409-0001$32.00/0
doi:10.1016/j.bbmt.2008.06.013Long-Term follow-up of a Phase I/II Randomized,
Placebo-Controlled Trial of Palifermin to Prevent
Graft-versus-Host Disease (GVHD) after Related Donor
Allogeneic Hematopoietic Cell Transplantation (HCT)John E. Levine,1,2 Bruce R. Blazar,3,4 Todd DeFor,3 James L. M. Ferrara,1,2 Daniel J. Weisdorf 3,5
1Department of Pediatrics, Blood and Marrow Transplantation Program, and 2Department of Internal Medicine,
Blood and Marrow Transplantation Program, University of Michigan, Ann Arbor, Michigan; 3Blood and Marrow
Transplant Program, 4Division of Pediatric Hematology, Oncology and Transplantation, and 5Division of Medical
Hematology, University of Minnesota, Minneapolis, Minnesota
Correspondence and reprint requests: John E. Levine, MD, MS, Blood and Marrow Transplant Program, 5303 Cancer
Center, 1500 E. Medical Center Drive, Ann Arbor, MI 48109-5941 (e-mail: jelevine@umich.edu).
Received May 15, 2008; accepted June 17, 2008
ABSTRACT
We previously conducted a randomized, double-blind, placebo-controlled study conducted from 2000 to 2003 of
palifermin, a recombinant humankeratinocyte growth factor, dosed from240mg/kg to 720mg/kg, in 100 allogeneic
hematopoietic stemcell transplantation (HCT) recipients.Treatmentwith palifermin showedbeneficial effects on
mucositis, but no significant effect on engraftment, acute graft-versus-host disease (GVHD), or early survival. In
addition to the effect of palifermin on mucosa, other pleotrophic effects, including more rapid immune reconsti-
tution, have been seen in experimental transplantmodels. Therefore, we investigated whether with longer follow-
up we could detect additional differences between the palifermin-treated and placebo cohorts. We found no
differences in CMV or invasive fungal infections, chronic GVHD, or long-term survival between cohorts. We
conclude that the benefits of palifermin appear primarily to be limited to ameliorating mucotoxicity when given
to allogeneic HCT recipients.
 2008 American Society for Blood and Marrow Transplantation
KEY WORDS
Palifermin  GVHD  Hematopoietic stem cell transplantationINTRODUCTION
Allogeneic hematopoietic cell transplantation
(HCT) represents the only curative therapy for large
numbers of patients with hematologic malignancies.
A major advantage of allogeneic HCT is the potential
for graft-versus-leukemia (GVl) effects, which can
reduce the risk of relapse and improve survival. How-
ever, there is a tight association between GVL and
graft-versus-host disease (GVHD), and GVHD con-
tinues to be the major contributor to posttransplant
morbidity and mortality. The pathophysiology of
GVHD is complex, but involves inflammatory
cytokine effectors, amplified by translocation of lipo-
polysaccharide (LPS) across damaged gastrointestinal
epithelium [1,2]. Therefore, protection of the gastro-
intestinal (GI) tract from HCT conditioning-inducedinjury has the potential to ameliorate the GI tract con-
tribution to GVHD.
Palifermin (keratinocyte growth factor [KGF]) has
proved to be effective at preventing chemotherapeutic
or radiationGI injury in the setting of high-dose autol-
ogous HCT [3]. Furthermore, preclinical animal
models showed that palifermin reduced the severity
of acute GVHD (aGVHD) arising after allogeneic
HCT [4-6]. An additional potential benefit of palifer-
minmay be improved thymopoiesis and peripheral im-
mune reconstitution, as has been seen in experimental
models of GVHD [7,8].
To determine the potential benefits of palifermin
in the allogeneic HCT setting, we conducted a phase
I/II randomized, placebo-controlled trial of palifermin
in 100 patients undergoing matched, related-donor1017
1018 J. E. Levine et al.HCT following myeloablative therapy at the Univer-
sity of Minnesota and the University of Michigan
from 2000 to 2003. The results of this trial have
been reported [9], and contrary to expectations, pali-
fermin administration before and after HCT had no
significant effect on the incidence and severity of
aGVHD, survival to day 100, or relapse rates. We
now update this data with longer follow-up, and report
infection rates observed during this study.
PATIENTS, MATERIALS, AND METHODS
Patient and Transplant Characteristics
The patients characteristics have been previously
reported [9]. Briefly, 100 patients were enrolled on
the study: 31 patients randomly assigned to receive
placebo and 69 to receive 1 of 4 doses and schedules
of palifermin. Two patients who were randomized to
palifermin did not undergo transplant (death and pa-
tient decision) and were not further analyzed. Baseline
demographic and disease characteristics were balanced
between the placebo and palifermin cohort with re-
spect to center (Michigan or Minnesota), sex, age,
weight, year of transplant, and disease treated (Table
1). The median age for placebo patients was 46
(7-63) years and for palifermin patients was 46 (7-65)
Table 1. Patient Characteristics
N Placebo Palifermin P
Total 100 31 60
Center .91
Michigan 46 14 32
Minnesota 54 17 37
Gender .99
Male 58 18 40
Female 42 13 29
Median Age, years (range) 46 (7-63) 46 (7-65) .58
Disease .08
ALL 9 1 8
AML 36 12 24
CML 15 8 7
MDS 12 6 6
NHL 14 1 13
Hodgkin 1 0 1
Other malignancy 13 3 10
AML indicates acutemyelogenous leukemia; CML, chronicmyelog-
enous leukemia; MDS, myelodysplastic syndrome; NHL,
non-Hodgkin lymphoma.years. Median follow-up of 365 days is the same be-
tween placebo and palifermin treated patients.
All patients received a myeloablative allogeneic
HCT from a HLA genotypically identical sibling
donor. Conditioning regimens consisted of either
cyclophosphamide (120 mg/kg) and fractionated to-
tal-body irradiation (TBI) (1320 cGy) (University of
Minnesota) or oral busulfan (16 mg/kg) and cyclo-
phosphamide (120 mg/kg) (University of Michigan).
GVHD Prophylaxis
GVHD prophylaxis consisted of a calcineurin in-
hibitor (tacrolimus or cyclosporine) and short-course
methotrexate (MTX; 15 mg/m2 on day 1 and 10 mg/m2
on days 3, 6, and 11).
Study Design
The study utilized a randomized, double-blind, pla-
cebo-controlled, dose-escalation design. Three palifer-
min cohorts were sequentially enrolled with dose
escalation of palifermin for each cohort. All cohorts re-
ceived 3 days of palifermin at 40 mg/kg (8 patients) or 60
mg/kg (61 patients) prior to the start of conditioning
therapy and then received the same dose of palifermin
on 3 consecutive days weekly starting day 0 for 1 (18 pa-
tients), 2 (14patients), or3 (37patients)weeks.Thus, the
total palifermindose ranged from240mg/kg for the low-
est dose cohort to 720mg/kg for the highest dose cohort.
Patientswere randomized topaliferminorplacebousing
a 1:2 scheme and structured to achieve balance within
each study site and in each cohort with stratification
based on conditioning regimen and patient age.
Follow-up Design
Patient study charts and transplant center database
records were reviewed. Chronic GVHD (cGVHD)
was recorded by date of onset and organs involved. cy-
tomegalovirus (CMV) detection by antigenemia or
bloodDNApolymerase chain reaction (PCR)was con-
sidered evidence as CMV reactivation if there was
more than 1 positive result with no intervening nega-
tive studies. CMV infections were categorized as vire-
mia, in the absence of organ involvement, or as disease,
if there was end organ involvement with CMV as dem-
onstrated by biopsy or organ dysfunction in the setting
of documented viremia. Invasive fungal infectionsTable 2. Cumulative Incidence of Chronic GVHD (cGVHD)
N No. with cGVHD
2 Year Cumulative
Incidence (95% CI) P
2-Year Competing
Risk (95% CI) P
Total 98 53 54% (43% 65%) 27% (18%-36%)
Placebo 31 17 55% (35% 75%) .65 32% (16%-48%) .26
Palifermin 67 36 53% (39% 67%) 25% (15%-35%)
The competing risks (death without cGVHD) are shown.
CI indicates confidence interval.
(proved or probable) required documentation with
positive culture or cytologic/histologic results.
Statistical Methods
The primary endpoints in this follow-up study
were cGVHD at 2 years, the probabilities of overall
survival (OS) at 2 years and the incidence of serious vi-
ral and fungal opportunistic infections.
Diagnosis of cGVHD was based on standard clin-
ical criteria [10] with histopathologic confirmation
where possible. The cumulative incidence of GVHD
was calculated by treating deaths from other causes
as competing risks. Probabilities and 95% confidence
intervals [CI] of infections and cGVHD, were calcu-
lated using the cumulative incidence function [11].
The statistical endpoint of OS was estimated by the
Kaplan-Meier method [12].
Statistical comparison of time-to-event curves was
completed by the log-rank test. Comparison of the
demographic factors was performed by the chi-square
test or Fischer’s exact test if patient numbers were
small. Continuous factors were compared by the non-
parametric general-wilcoxon test.
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Figure 1. Cumulative incidence of cGVHD in the palifermin-
treated and placebo cohorts.
Palifermin in Allogeneic HCT RecipientsRESULTS
GVHD
As originally reported, there was no significant dif-
ference in the incidence of grades II-IV or grades III-
IV aGVHD in patients receiving palifermin compared
to placebo, nor was there a difference in involvement
or severity of individual organs. As shown in Table 2
and Figure 1, the cumulative incidence of cGVHD
was nearly identical for both the palifermin and pla-
cebo cohorts (55% versus 53%, P 5 .65). There
were no statistically significant differences in time to
onset of cGVHD or organ involvement.
Infections
As shown in Table 3, the 1-year cumulative inci-
dence of CMV infection was 16% for both the palifer-
min and placebo cohorts (P 5 .94). There was no
evidence of a protective effect during the first 100
days after transplant (when CMV infections are most
likely to occur) nor was there a trend for decreasing
CMV infection rates with increasing palifermin dose.
Palifermin administration was not associated with
protection against invasive fungal infections. Yeasts
were the predominant fungal infection encompassing
26 of 28 cases in palifermin-treated patients and all 9 in-
vasive fungal infections in the placebo cohort. In addi-
tion to yeast infections, there was 1 aspergillus and 1
penicillium infection in the palifermin-treated patients.
As shown inTable 3, the 1-year cumulative incidence of
invasive fungal infections was 41% for the palifermin
cohort and 29% for the placebo cohort (P 5 .38).
Survival
We previously reported that palifermin did not
provide a survival benefit for survival during the first
100 days. This lack of benefit did not change over
time as the 2-year survival for the palifermin cohort
versus the placebo cohort was 46% versus 58%,
respectively, P 5 .42 (Table 4 and Figure 2).
1019Table 3. Cumulative Incidence of Infections
Infections N
No. with
Infections
100 Days
(95% CI) 1 Year (95% CI) P
1 Year
Competing
Risk(95% CI) P
CMV infections
Total 98 16 15% (8%-22%) 16% (9%-23%) 30% (21%-39%)
Palifermin 67 11 16% (7%-25%) 16% (7%-25%) .94 29% (18%-30%) .65
Placebo 31 5 13% (2%-24%) 16% (3%-29%) 32% (15%-49%)
Fungal infections
Total 98 37 28% (19%-37%) 37% (27%-47%) 20% (12%-28%)
Palifermin 67 28 29% (18%-40%) 41% (29%-53%) .38 19% (10%-28%) .65
Placebo 31 9 26% (11%-41%) 29% (13%-45%) 23% (8%-38%)
The competing risks (death without infection) are shown.
CI indicates confidence interval.
1020 J. E. Levine et al.Table 4. Survival at 100 days, 1 Year, and 2 Years from HCT
Survival N No. Dead
100-Day
Survival (95% CI)
1 Year
(95% CI) P
2 Year
(95% CI) P
Total 98 49 83% (76%-90%) 59% (49%-69%) 50% (40%-60%)
Palifermin 67 36 82% (73%-91%) 58% (46%-70%) .85 46% (34%-58%) .42
Placebo 31 13 84% (71%-97%) 61% (44%-78%) 58% (41%-75%)DISCUSSION
Our previous study demonstrated that palifermin
could be safely administered to patients undergoing
allogeneicHCT.Althoughnotmonitoredonadaily ba-
sis, we also showed that palifermin reduced mucositis
severity in patients undergoing a cyclophosphamide
(Cy)/total body irradiation (TBI) conditioning regi-
men, but not in patients receiving the less mucotoxic
regimen of busulfan and cyclophosphamide. At these
doses and schedules, palifermin did not alter the inci-
dence, organ involvement, or severity of aGVHD, nor
did it protect against death. Unanswered at the time
of the original publication, however, was whether pali-
fermin may have conferred protection against infec-
tions, cGVHD, or late mortality. We now conclude
that cGVHD was unaffected in this study.
Animal studies in rodents indicated that palifermin
can reduce aGVHD-associated lethality when given
withTBI [5,6].However, the potency of this protective
effect varied between models and severity of the
aGVHD lethality in controls. When TBI was com-
bined with Cy, aGVHD was more aggressive and pal-
ifermin rescued 13% of mice from lethality as
assessed at the conclusion of the study (5.5 weeks
post-BMT) [5]. In these latter studies, a transient epi-
thelial protective effect by palifermin was observed
on day 7 but not at later times post-BMT. Therefore,
the clinical data on aGVHD lethality in cyclophospha-
mide and TBI-conditioned rodents is similar in many
respects to the aGVHD results in this human clinical
trial. Both rodent [13,14] , and nonhuman primates
[15] studies have demonstrated that palifermin protects
thymic epithelium from radiation-induced damage re-
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Figure 2. Kaplan-Meier survival curves for the palifermin-treated
and placebo cohorts.sulting in improved thymopoiesis and peripheral im-
mune recovery. We were not able to perform detailed
immune recovery assays; therefore, we cannot con-
clude that palifermin does not alter immune recovery
in a favorable way. However, in this study we observed
no evidence of clinical benefit in terms of reduced fun-
gal or CMV infections in the palifermin cohort.
Themechanisms that lead to cGVHD are complex
and poorly understood, but a major risk factor for
cGVHD is preceding aGVHD [16]. Therefore, it is
perhaps not surprising that we observed no reduction
in the incidence of cGVHD in the palifermin cohort.
It, therefore, follows that 1-year survival was not im-
proved in the palifermin cohort, given the major role
GVHD plays in treatment-related mortality (TRM),
particularly following the first few months. A lack of
survival benefit with palifermin was previously re-
ported in the autologous HCT setting [3].
Palifermin is routinely administered to reduce the
severity, incidence, and duration of mucositis follow-
ing autologous HCT, and we have previously reported
a similar benefit in the allogeneic setting when using
highly mucotoxic regimens. However, palifermin,
when administered in the doses and schedule used in
this study, resulted in no long-term benefit. Results
of ongoing studies in other allogeneic HCT trials
will determine whether the aGVHD and cGVHD
results seen in palifermin-treated patients enrolled on
this trial can be extrapolated to other clinical venues.
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